• 1
    Sirica AE. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol 2008; 14: 7033-7058.
  • 2
    Kiguchi K, Carbajal S, Chan K, Beltrán L, Ruffino L, Shen J, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 2001; 61: 6971-6976.
  • 3
    Lai G-H, Zhang Z, Shen X-N, Ward DJ, DeWitt JL, Holt SE, et al. erbB-2/neu Transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 2005; 129: 2047-2057.
  • 4
    Sirica AE, Zhang Z, Lai G-H, Asano T, Shen X-N, Ward DJ, et al. A novel “patient-like” model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. HEPATOLOGY 2008; 47: 1178-1190.
  • 5
    Lai G-H, Sirica AE. Establishment of a novel rat cholangiocarcinoma cell culture model. Carcinogenesis 1999; 20: 2335-2340.
  • 6
    Lai G-H, Zhang Z, Sirica AE. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases -9 and -3. Mol Cancer Ther 2003; 2: 265-271.
  • 7
    Radaeva S, Ferreira-Gonzalez A, Sirica AE. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. HEPATOLOGY 1999; 29: 1453-1462.
  • 8
    Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. HEPATOLOGY 2002; 36: 439-450.
  • 9
    Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
  • 10
    Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
  • 11
    Wiedmann M, Feisthammel J, Blüthner T, Tannapfel A, Kamenz T, Kluge A, et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs 2006; 17: 783-795.
  • 12
    Kiguchi K, Ruffino L, Kawamoto T, Ajiki T, DiGiovanni J. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder cancer. Clin Cancer Res 2005; 11: 5572-5580.
  • 13
    Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz H-J, Yen Y, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64: 777-783.
  • 14
    Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 2005; 206: 356-365.
  • 15
    Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, et al. HER receptor family: novel candidate for targeted therapy for gallbladder and extrahepatic bile duct cancer. Gastrointest Cancer Res 2007; 1: 221-227.
  • 16
    Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Brit J Cancer 2008; 98: 418-425.
  • 17
    Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009; 15: 4511-4517.
  • 18
    Shafizadeh N, Grenert JP, Sahai V, Kakar S. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol 2010; 41: 485-492.
  • 19
    Yoshikawa D, Ojima H, Kokuba A, Ochiya T, Kasai S, Hirohashi S, et al. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signaling, as a novel molecular-targeted therapy against cholangiocarcinoma. Brit J Cancer 2009; 100: 1257-1266.
  • 20
    Obama K, Ura K, Li M, Katagiri T, Tsunoda T, Nomura A, et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. HEPATOLOGY 2005; 41: 1339-1348.
  • 21
    Su W-C, Shiesh S-C, Liu H-S, Chen C-Y, Chow N-H, Lin X-Z. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-β, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci 2001; 46: 1387-1392.
  • 22
    Sirica AE, Dumur CI, Campbell DJW, Almenara JA, Ogunwobi OO, DeWitt JL. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol 2009; 7: S68-S78.
  • 23
    Zhou Y, Brattain MG. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human carcinoma cells is associated with induction of apoptosis. Cancer Res 2005; 65: 5848-5856.
  • 24
    Hu YP, Venkateswarlu S, Sergina N, Howell G, St Clair P, Humphrey LE, et al. Reorganization of ErbB family and cell survival signaling after knock-down of ErbB2 in colon cancer cells. J Biol Chem 2005; 280: 27383-27392.
  • 25
    Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P, et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005; 65: 3003-3010.
  • 26
    Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, et al. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2008; 7: 1846-1850.
  • 27
    Kim HJ, Kim JS, Kang CD, Lee SJ, Kim JY, Yeon JE, et al. Expression of epidermal growth factor receptor, ErbB2 and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma. Korean J Gastroenterol 2005; 45: 52-59.